Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at assumed coverage on shares of Aethlon Medical (NASDAQ:AEMDFree Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price objective on Aethlon Medical from $23.00 to $10.00 and set a buy rating for the company in a research note on Monday, March 4th.

View Our Latest Report on AEMD

Aethlon Medical Stock Performance

Aethlon Medical stock opened at $0.40 on Thursday. Aethlon Medical has a fifty-two week low of $0.37 and a fifty-two week high of $5.00. The company has a market capitalization of $1.05 million, a P/E ratio of -0.08 and a beta of 1.95. The stock has a 50-day simple moving average of $1.23 and a 200-day simple moving average of $1.62.

Aethlon Medical Company Profile

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.

Recommended Stories

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.